^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
10/30/2020
Excerpt:
Gastrointestinal Stromal Tumors: First-line therapy…Preferred Regimens…Imatinib (category 1)...
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Gastrointestinal Stromal Tumors: Systemic Therapy agents and regimens for unresectable GIST with significant morbidity...Useful in certain circumstances…Everolimus + TKI…TKIs to be considered for use in combination with everolimus include imatinib, sunitinib, or regorafenib
Secondary therapy:
everolimus
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)

Published date:
01/19/2021
Excerpt:
With 9.1 years of follow-up, a trend toward better long-term IFFS in imatinib-treated patients was observed in the high-risk subgroup...the results reported by the Scandinavian/German trial, showing a sustained small but significant long-term OS benefit in high risk GIST patients treated with 3 years of adjuvant imatinib.
DOI:
10.1016/j.annonc.2021.01.004
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Published date:
08/01/2020
Excerpt:
To evaluate the effect of adjuvant imatinib on OS of patients who have a high estimated risk for GIST recurrence after macroscopically complete surgery....In the 36-month group, 5-year OS and 10-year OS rates were 92.0% and 79.0%, respectively, and in the 12-month group 85.5% and 65.3% (HR, 0.55; 95% CI, 0.37-0.83; P = .004)....Three years of adjuvant imatinib is superior in efficacy compared with 1 year of imatinib.
DOI:
10.1001/jamaoncol.2020.2091